Exploring pyrazolo[3,4-d]pyrimidine phosphodiesterase 1 (PDE1) inhibitors: a predictive approach combining...

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Neuroscience

Background:

• Phosphodiesterase 1 (PDE1) is a therapeutic target for neurodegenerative disorders including Schizophrenia, Parkinson's, and Alzheimer's diseases.
• Understanding the structure-activity relationships of PDE1 inhibitors is crucial for drug discovery.

Purpose of the Study:

• To elucidate the physicochemical and structural requirements for enhanced phosphodiesterase 1 (PDE1) inhibitory activity.
• To identify key molecular features of pyrazolo[3,4-d]pyrimidine derivatives responsible for PDE1 inhibition.

Main Methods:

• Employed diverse molecular modeling techniques, including quantitative structure-activity relationship (QSAR) studies (regression-based and classification-based), Monte Carlo simulations, Open3DQSAR, pharmacophore mapping, and molecular docking.
• Analyzed a series of pyrazolo[3,4-d]pyrimidine compounds targeting PDE1.

Main Results:

• The planarity of the pyrimidinone ring, N-methylation at the 5th position, fused cyclopentyl ring, and phenylamino substitution at the 3rd position are critical for PDE1 inhibition.
• N2-substitution on the pyrazole moiety, particularly with a p-substituted benzyl side chain, significantly enhances PDE1 inhibitory activity compared to N1-substituted analogs.
• Specific structural features were identified as essential for potent binding and inhibition of the PDE1 enzyme.

Conclusions:

• The study provides detailed insights into the structural determinants of PDE1 inhibition by pyrazolo[3,4-d]pyrimidine derivatives.
• These findings facilitate the rational design of novel, more potent PDE1 inhibitors for potential therapeutic applications in neurodegenerative diseases.
• New candidate molecules with improved PDE1 inhibitory profiles have been predicted based on the established structure-activity relationships.